secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sonoma Pharmaceuticals, Inc. (SNOA)
CIK:        0001367083
Form:       8-K
Filed at:   2023-09-28T23:59:59+00:00
Accession:  0001683168-23-006809
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 3.01, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Sonoma Pharma receives Nasdaq delisting notice for bid price non-compliance; say-on-pay vote fails
--------------------------------------------------------------------------------

- Received Nasdaq notice on Sept 22, 2023 for failure to maintain $1 minimum bid price for 30 consecutive days.
- Granted 180-day compliance period until March 20, 2024; needs $1 closing bid for 10 consecutive business days.
- Annual meeting on Sept 28, 2023: non-binding advisory vote on executive compensation did NOT pass (560,065 for, 290,657 against, 8,188 abstain).
- Stockholders ratified Frazier & Deeter as independent auditor for FY ending March 31, 2024 (2,560,351 for, 41,495 against, 3,765 abstain).
- Jerry McLaughlin elected Class III director with 552,672 for, 306,238 withheld.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367083/000168316823006809/0001683168-23-006809-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367083/000168316823006809/sonoma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-006809

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer